Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
coagulation factor ix recombinant human + isopropyl alcohol
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Coagulation factor ix recombinant human + isopropyl alcohol is a specific formulation associated with **BeneFIX**, consisting of recombinant human coagulation factor IX as the therapeutic active component together with isopropyl alcohol as part of the preparation. The recombinant factor IX component functions as **replacement therapy** for patients with hemophilia B, restoring deficient factor IX activity in the coagulation cascade and thereby improving thrombin generation and hemostasis. This product is a **recombinant protein biologic** administered **intravenously after reconstitution**, and is used under the supervision of clinicians experienced in the management of hemophilia B. BeneFIX was developed and is marketed by Pfizer.
- Brand names
- BeneFIX
- Other names
- coagulation factor ix recombinant human + isopropyl alcoholrecombinant factor ix + isopropyl alcoholnonacog alfa + isopropyl alcohol
02
Targets
F9 (Coagulation Factor IX)
Beyond the preview
Go deeper on coagulation factor ix recombinant human + isopropyl alcohol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on coagulation factor ix recombinant human + isopropyl alcohol.